The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Dr. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

JANUARY 19, 2021

The company hopes to raise $140 million of common stock, which will be used to advance its clinical and earlier stage programs and for R&D, working capital and general corporate purposes. TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. With this kind of a start, 2021 may be scorching.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

The Pharma Data

AUGUST 16, 2020

First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks. First and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology.

FDA Approval 52

FDA Approval Antibody Clinical Trials Clinical Trials 52

The Pharma Data

MAY 15, 2023

Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development. “If If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.”

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

NOVEMBER 12, 2021

COMET-TAIL Phase III data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations The trial enrolled participants during the Delta variant wave of the pandemic in the US. GlaxoSmithKline plc (LSE/ NYSE GSK) and Vir Biotechnology,Inc.

Trials 40

Trials In-Vitro Antibody Clinical Development 40

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. Chief Medical Officer and Head of Global Product Development.

Antibody 40

Antibody In-Vitro Development Trials 40

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

SEPTEMBER 9, 2020

Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD. Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD. Roche’s Chief Medical Officer and Head of Global Product Development. ENSPRYNG was recently approved by the U.S.

Antibody 52

Antibody Medicine HR In-Vitro 52

The Pharma Data

JUNE 26, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development. Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Roche-sponsored global trials included the placebo-controlled EMPACTA, COVACTA and REMDACTA studies.

Clinical Trials 40

Clinical Trials Clinical Trials In-Vitro Antibody 40

Pharmaceutical Technology

AUGUST 26, 2008

“It has to be recognised that antibody therapy does not fit everyone and that small molecule therapy may be more appropriate for some people due to cost considerations.” It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals.

Antibody 130

Antibody Licensing Licensing Production 130

Drug Discovery World

DECEMBER 13, 2023

Dual inhibition of both CD73 and PD-1 checkpoint pathways with a single DFC contributed to significant tumour growth reduction, highlighting the potential clinical benefits of this first-in-class multi-specific inhibitor derived from our Cloudbreak platform.”

In-Vitro 52

In-Vitro Drugs Antibody Clinical Development 52

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

HR 52

HR Medicine In-Vitro Development 52

XTalks

NOVEMBER 15, 2023

XTALKS WEBINAR: Vaccine Clinical Development: Key Ingredients to Improve Efficiency Live and On-Demand: Monday, November 20, 2023, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn ways to improve the efficiency of vaccine development. Fever and joint pain are the most common symptoms of chikungunya.

FDA Approval 59

FDA Approval Vaccination Vaccine In-Vitro 59

The Pharma Data

SEPTEMBER 16, 2020

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Roche’s Chief Medical Officer and Head of Global Product Development. “As New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers.

HR 52

HR Medicine Hormones Trials 52

Drug Discovery World

FEBRUARY 15, 2023

Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6. Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets).

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

MARCH 26, 2021

The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial, which evaluated VIR-7831 as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalisation.

Antibody 52

Antibody Trials Vaccination Vaccine 52

The Pharma Data

MAY 18, 2021

If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EU. Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development.

Antibody 40

Antibody Medicine In-Vitro Development 40

The Pharma Data

SEPTEMBER 2, 2020

Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations. Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Medicine 52

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. And in truth, the companies the White House picked were pretty savvy as several are current front-runners in the race to develop a vaccine. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92